Dermatology News and Research

Latest Dermatology News and Research

Statins linked to reduced glaucoma risk

Cholesterol-lowering medications in the statin class could significantly reduce the risk for developing open-angle glaucoma, show data for more than 500,000 older-age US individuals with hyperlipidemia.

2 Oct 2012

HDL may protect against abdominal aortic aneurysm

High levels of high-density lipoprotein cholesterol inhibit the formation of abdominal aortic aneurysm, findings from experimental mouse models suggest.

2 Oct 2012

$Stent fracture after stent implantation linked to thrombosis$

Stent fracture after stent implantation linked to thrombosis

Stent fracture after everolimus-eluting stent implantation occurs in 2.9% of lesions and is associated with a significantly increased rate of major adverse cardiac events, say researchers.

2 Oct 2012

Coding the way to better occupational allergy care

The 11th draft of the International Classification of Diseases, due to be released in 2015, will allow a much more detailed specification of occupational allergy and contact dermatitis than the current draft, say dermatologists involved in the revision.

1 Oct 2012

New treatment target brings hope for scleroderma patients

Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in scleroderma patients.

1 Oct 2012

Oil blend plus antihypertensive lowers blood pressure, cholesterol level

A blend of sesame and rice bran oil could reduce blood pressure by almost as much as an antihypertensive medication, say researchers.

1 Oct 2012

PLATO: Causes of lower mortality with ticagrelor identified

The mortality reduction with ticagrelor versus clopidogrel is due to fewer deaths from cardiovascular, bleeding, and infection complications, say researchers.

1 Oct 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.

29 Sep 2012

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

28 Sep 2012

Sunshine vitamin affects cardiac outcomes

Vitamin D deficiency could increase the risk for ischemic heart disease, myocardial infarction, and early death, researchers suggest.

27 Sep 2012

Novel oral anticoagulant bleeding risk offsets clinical benefit

The use of orally activated Xa antagonist and direct thrombin inhibitors is associated with a significant increase in major bleeding events in acute coronary syndrome patients, a study shows.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012